SELLAS Life Sciences Group Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

SELLAS Life Sciences Group şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

-3.7%

Geri Alım Getirisi

Toplam Hissedar Getirisi	-3.7%
Gelecekteki Temettü Verimi	n/a
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Güncelleme yok

Recent updates

Analiz Makalesi • Oct 08

Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Analiz Makalesi • Jun 25

Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

Just because a business does not make any money, does not mean that the stock will go down. For example, although...

Analiz Makalesi • Nov 23

SELLAS Life Sciences rises 9% after cancer drug shows promising result in animal study

SELLAS Life Sciences (NASDAQ:SLS) is trading 9.2% higher on Tuesday after the company announced results from preclinical studies for its CDK9 inhibitor, GFH009, to treat solid cancer and acute myeloid leukemia (AML) cell lines. The drug showed significant anti-tumor effects in all four selected cell lines, and in three out of the four cell lines, GFH009 inhibited cancer cell growth by 90% to 100%. The following cell lines were selected for the studies: RH30: a pediatric soft tissue sarcoma cell line. NCI-H209: a small cell lung cancer cell line. SKOV-3: an ovarian cancer cell line. OCI-AML-2: an AML cell line. "The data from preclinical studies that we are reporting today demonstrates that certain cancer cell lines, whose survival depends on specific changes in the cell, can be identified and treated with GFH009," said Dragan Cicic, Senior Vice President, Clinical Development, of SELLAS.

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: SLS şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: SLS şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

SELLAS Life Sciences Group Piyasaya Karşı Temettü Getirisi

SLS temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (SLS)	n/a
Pazarın Alt %25'i (US)	1.4%
Pazarın En İyi %25'i (US)	4.2%
Sektör Ortalaması (Biotechs)	2.4%
Analist tahmini (SLS) (3 yıla kadar)	n/a

Önemli Temettü: SLS şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, SLS şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: SLS şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: SLS herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Güçlü temettü ödeyen şirketleri keşfedin

Şirket Analizi ve Finansal Veri Durumu

Veri	Son Güncelleme (UTC saati)
Şirket Analizi	2026/05/27 13:43
Gün Sonu Hisse Fiyatı	2026/05/27 00:00
Kazançlar	2026/03/31
Yıllık Kazançlar	2025/12/31

Veri Kaynakları

Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.

Paket	Veri	Zaman Çerçevesi	Örnek ABD Kaynağı ^*
Şirket Finansalları	10 yıl	Gelir tablosu Nakit akış tablosu Bilanço	SEC Form 10-K SEC Form 10-Q
Analist Konsensüs Tahminleri	+3 yıl	Finansal tahminler Analist fiyat hedefleri	Analist Araştırma Raporları Blue Matrix
Piyasa Fiyatları	30 yıl	Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler	ICE Piyasa Verileri SEC Form S-1
Sahiplik	10 yıl	En büyük hissedarlar İçeriden öğrenenlerin ticareti	SEC Form 4 SEC Form 13D
Yönetim	10 yıl	Liderlik ekibi Yönetim Kurulu	SEC Form 10-K SEC Form DEF 14A
Önemli Gelişmeler	10 yıl	Şirket duyuruları	SEC Form 8-K

* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılmıştır.

Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Daha fazla bilgi edinin.

Analiz Modeli ve Kar Tanesi

Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntılarına GitHub sayfamızdan ulaşabilirsiniz, ayrıca raporlarımızı nasıl kullanacağınızı anlatan kılavuzlarımız ve Youtube'da eğitim videolarımız da bulunmaktadır.

Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.

Endüstri ve Sektör Metrikleri

Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları Github'da mevcuttur.

Analist Kaynakları

SELLAS Life Sciences Group, Inc. 4 Bu analistlerden 2, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.

Analist	Kurum
James Molloy	Alliance Global Partners
Aydin Huseynov	Ladenburg Thalmann & Company
Jason McCarthy	Maxim Group

SELLAS Life Sciences Group Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Recent updates

SELLAS Life Sciences Awaits Key AML Phase 3 Results as Stock Sees Swings and Cash Position Grows

No longer forecast to breakeven

SELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 16, 2026

SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering in the amount of $150 million.

New minor risk - Profitability

Sellas Life Sciences Group Announces Preclinical Data On SLS009 In AML

Sellas Life Sciences Group Announces Enrollment of First Patient in Newly Diagnosed First-Line AML Trial of SLS009

New major risk - Share price stability

SELLAS Life Sciences Group, Inc. Provides Update on Pivotal Phase 3 Regal Trial of Galinpepimut-S (GPS) in Acute Myeloid Leukemia

Forecast to breakeven in 2028

New minor risk - Share price stability

Independent Director recently bought US$101k worth of stock

Sellas Life Sciences Announces Presentation of Phase 2 Data of Sls009 in Combination with Azacitidine and Venetoclax in Relapsed/Refractory Aml with Mds-Related Changes (Aml-Mr) At the 2025 American Society of Hematology (Ash) Annual Meeting

New major risk - Financial position

SELLAS Life Sciences Group, Inc. to Present in Vivo Preclinical Data Demonstrating Statistically Significant Survival Benefit of SLS009 in T-Cell Prolymphocytic Leukemia AAt the European Society for Medical Oncology (ESMO) Congress 2025

Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

SELLAS Life Sciences Group Announces Virtual R&D Day on October 29, 2025, Featuring Updates on GPS and SLS009 Programs

SELLAS Life Sciences Announces Independent Data Monitoring Committee Periodic Review and Positive Recommendation to Continue Pivotal Phase 3 Regal Trial of GPS in AML Without Modification

Sellas Life Sciences Group, Inc. Meets All Primary Endpoints in Phase 2 Trial of Sls009 in R/R Aml and Receives Fda Guidance to Advance into First-Line Therapy Study

SELLAS Life Sciences Group, Inc. Appoints Linghua Wang to Scientific Advisory Board

New minor risk - Share price stability

Is SELLAS Life Sciences Group (NASDAQ:SLS) In A Good Position To Invest In Growth?

New minor risk - Profitability

Sellas Life Sciences Group, Inc. Appoints Philip C. Amrein and Alex Kentsis to the Scientific Advisory Board

Sellas Life Sciences Group, Inc. Presents Preclinical Efficacy of Sls009 in Asxl1 Mutated Colorectal Cancer At 2025 Asco Annual Meeting

New major risk - Financial position

SELLAS Life Sciences Group, Inc. Announces First Pediatric AML Patient Dosed in the Ongoing Phase 2 Trial of Sls009 R/R AML

SELLAS Life Sciences Group, Inc. Unveils Breakthrough Preclinical Data Highlighting Efficacy of Sls009 in Tp53 Mutated AML At the 2025 AACR Conference

SELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 17, 2025

SELLAS Life Sciences Group, Inc. to Present At the 2025 American Society of Clinical Oncology Annual Meeting

SELLAS Life Sciences Group, Inc. Announces Cohort 3 Data from the Ongoing Phase 2 Trial of SLS009

No longer forecast to breakeven

SELLAS Life Sciences Group, Inc. Announces Positive Data from Phase 2a Trial of SLS009 in Combination with Zanubrutinib in DLBCL

SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering in the amount of $24.998852 million.

New minor risk - Share price stability

Sellas Life Sciences Group, Inc. Announces Positive Outcome of Interim Analysis for Its Pivotal Phase 3 Regal Trial of GPS in Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Triggers Interim Analysis in Phase 3 Regal Trial of GPS in Acute Myeloid Leukemia

SELLAS Announces Positive Overall Survival and Overall Response Rate Data from the Phase 2 Trial of SLS009 inr/r AML

SELLAS Life Sciences Group, Inc. Announces Positive Data from Preclinical Studies Indicating ASXL1 Mutations as Predictor of Response to SLS009 in Solid Cancers

Here's Why SELLAS Life Sciences Group (NASDAQ:SLS) Must Use Its Cash Wisely

New major risk - Financial position

SELLAS Announces U.S. FDA Rare Pediatric Disease Designation (RPDD) Granted to Galinpepimut-S (GPS) for the Treatment of Pediatric Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $20.999999 million.

SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering in the amount of $20.999999 million.

SELLAS Life Sciences Group, Inc. Receives European Medicines Agency Orphan Drug Designation for SLS009 for the Treatment of Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Announces U.S. FDA Rare Pediatric Disease Designation Granted to Sls009 for the Treatment of Pediatric Acute Lymphoblastic Leukemia

SELLAS Life Sciences Group, Inc. Announces Positive Recommendation from the Independent Data Monitoring Committee of the Phase 3 REGAL Trial in Acute Myeloid Leukemia

SELLAS Life Sciences Group (NASDAQ:SLS) Will Have To Spend Its Cash Wisely

Price target decreased by 17% to US$5.83

SELLAS Life Sciences Group, Inc. Announces Positive Phase 2 Preliminary Data of SLS009 in r/r AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation At the Optimal Dose Level

SELLAS Life Sciences Group, Inc., Annual General Meeting, Jun 20, 2024

SELLAS Life Sciences Group, Inc. Announces Positive Recommendation of Independent Data Monitoring Committee Following Completion of Enrollment in REGAL Phase 3 Study

SELLAS Life Sciences Group, Inc. Announces Positive Topline Data from the Phase 2a Study of Sls009 in r/r AML

New major risk - Shareholder dilution

SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $19.999797 million.

SELLAS Life Sciences Group, Inc. has filed a Follow-on Equity Offering.

New major risk - Share price stability

SELLAS Life Sciences Group, Inc. Announces Executive Changes

SELLAS Life Sciences Receives Compliance Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement

SELLAS Life Sciences Group, Inc. Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients

SELLAS Life Sciences Group, Inc. has completed a Follow-on Equity Offering in the amount of $9 million.

SELLAS Life Sciences Group, Inc. Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma

Sellas Life Sciences Announces First Patients Enrolled in 60 Mg Dose Cohort in Phase 2A Clinical Trial of Sls009 in Acute Myeloid Leukemia

SELLAS Life Sciences Group Receives a Letter from the Nasdaq Stock Market

Sellas Life Sciences Announces Positive Recommendation from Regal Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Reaches Target Enrollment Ex-China in Phase 3 Regal Trial of Galinpepimut-S in Acute Myeloid Leukemia

Consensus EPS estimates fall by 19%

SELLAS Life Sciences Group, Inc. Receives Favorable FDA Type C Meeting Feedback on Chemistry, Manufacturing, and Controls Biologics License Application Filing Strategy for Galinpepimut-S

New major risk - Negative shareholders equity

SELLAS Life Sciences Group, Inc. Presents Positive Key Immunobiological and Clinical Data from Phase 1/2 Trial of galinpepimut-S in Combination with Keytruda in WT1+ Platinum-Resistant Advanced Ovarian Cancer at International Gynecologic Cancer Society 2023 Annual Global Meeting

New major risk - Shareholder dilution

SELLAS Life Sciences Group, Inc. Announces Positive Initial Topline Phase 2a Data of SLS009 in Acute Myeloid Leukemia

SELLAS Life Sciences Group, Inc. Provides Update on Phase 3 Regal Clinical Trial for Galinpepimut-S in Acute Myeloid Leukemia

SELLAS Announces First Patient Dosed in Phase Ib/II Trial of SLS009 (GFH009) in Relapsed/Refractory Peripheral T-cell Lymphomas

New minor risk - Share price stability